Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...
USGBC accelerates and scales transformation of the built environment to minimize climate impacts and enhance the well-being of people, the environment and communities worldwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback